Patent EA-002967-B1 (EA)
Title: Medical compositions for application to mucosa
Inventor: NISHIBE YOSHIHISA
IPC: A61K9/10
Filed: 1999-04-21
Abstract: 1. An aqueous pharmaceutical composition for application to the mucosa, comprising one or more water-insoluble and/or water-low soluble substance, and one or more medicament, and having an osmotic pressure from 0 to 290 mOsm. 2. An aqueous pharmaceutical composition for application to the mucosa according to Claim 1, comprising one or more hemostatic agent. 3. The pharmaceutical composition for application to the mucosa according to Claim 1 or 2, wherein said osmotic pressure is 150 mOsm or less. 4. The pharmaceutical composition for application to the mucosa according to Claim 1 or 2, wherein said osmotic pressure is 60 mOsm or less. 5. The pharmaceutical composition for application to the mucosa according to Claim 1 or 2, wherein said osmotic pressure is 30 mOsm or less. 6. The pharmaceutical composition for application to the mucosa according to Claim 1 or 2, wherein said osmotic pressure is 10 mOsm or less. 7. The pharmaceutical composition for application to the mucosa according to Claim 1 or any of Claims 2 to 6, further comprising an osmotic pressure-controlling agent. 8. The pharmaceutical composition for application to the mucosa according to Claim 7, wherein said osmotic pressure-controlling agent is a salt. 9. The pharmaceutical composition for application to the mucosa according to Claim 8, wherein said osmotic pressure-controlling agent is sodium chloride. 10. The pharmaceutical composition for application to the mucosa according to Claim 7, wherein said osmotic pressure-controlling agent is a water-soluble sugar. 11. The pharmaceutical composition for application to the mucosa according to Claim 10, wherein said osmotic pressure-controlling agent is glucose. 12. The pharmaceutical composition for application to the mucosa according to Claim 1 or any of Claims 2 to 11, wherein said water-insoluble and/or water-low soluble substance is a cellulose. 13. The pharmaceutical composition for application to the mucosa according to Claim 12, wherein said cellulose is crystalline cellulose. 14. The pharmaceutical composition for application to the mucosa according to Claim 1 or any of Claims 2 to 11, wherein said one or more water-insoluble and/or water-low soluble substance is present as solid particles in an aqueous medium. 15. The pharmaceutical composition for application to the mucosa according to Claim 1 or any of Claims 2 to 11, wherein said one or more water-insoluble and/or water-low soluble substance is dispersed as solid particles in an aqueous medium. 16. The pharmaceutical composition for application to the mucosa according to Claim 1 or any of Claims 2 to 15, further comprising a water-soluble polymer substance. 17. The pharmaceutical composition for application to the mucosa according to Claim 16, wherein said water-soluble polymer is one or more selected from the group consisting of alginic acid, polyethylene glycol, glycerin, polyoxyethylene polyoxypropylene glycol, propylene glycol, pectin, low methoxyl pectin, guar gum, gum arabic, carrageenan, methyl cellulose, carboxymethyl cellulose sodium, xanthan gum, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose. 18. The pharmaceutical composition for application to the mucosa according to Claim 17, wherein said water-soluble polymer is carboxymethyl cellulose sodium. 19. The pharmaceutical composition for application to the mucosa according to Claim 17, wherein said water-soluble polymer is xanthan gum. 20. The pharmaceutical composition for application to the mucosa according to Claim 17, wherein said water-soluble polymer is hydroxypropyl methyl cellulose. 21. The pharmaceutical composition for application to the mucosa according to Claim 16, wherein the combination of said water-insoluble substance and water-soluble polymer is crystalline cellulose carmellose sodium. 22. The pharmaceutical composition for application to the mucosa according to any of Claims 1 or 2 to 21, further comprising a surfactant. 23. The pharmaceutical composition for application to the mucosa according to Claim 22, wherein said surfactant is polysorbate 80. 24. The pharmaceutical composition for application to the mucosa according to any of Claims 1 or 2 to 23, wherein said medicament is a water-soluble medicament. 25. The pharmaceutical composition for application to the mucosa according to any of Claims 1 or 2 to 23, wherein said medicament is a liposoluble medicament. 26. The pharmaceutical composition for application to the mucosa according to any of Claims 1 or 2 to 25, wherein said mucosa is nasal mucosa. 27. The pharmaceutical composition for application to the mucosa according to any of Claims 2 to 26, wherein said hemostatic agent is one or more selected from the group consisting of tranexamic acid, epsilon aminocaproic acid, carbazochrome, carbazochrome sulfonate, carbazochrome sodium sulfonate, phytonadione, etamsylate, monoethanol amine oleate, thrombin, hemocoaglase, and adrenochrome monoaminoguanidine mesilate. 28. The pharmaceutical composition for application to the mucosa according to any of Claims 2 to 27, wherein the agent other than said hemostatic agent is one or more selected from the group consisting of an antiallergic agent, an antihistamic agent, an anticholinergic agent, a steroid, a vaccine, and a substance for gene therapy, and the mucosa is nasal mucosa. 29. The pharmaceutical composition for application to nasal mucosa according to Claim 28, wherein the agent other than said hemostatic agent is a steroid.